Persistent inflammation is known to promote and exacerbate malignancy. Primary liver
cancer, mostly hepatocellular carcinoma (HCC), is a clear example of inflammation-related …

Hepatocellular carcinoma (HCC) represents a unique challenge for physicians and patients.
There is no definitively curative treatment. Rather, many treatment and management …

Since in most tumors multiple signaling pathways are involved, many of the inhibitors in
clinical development are designed to affect a wide range of targeted kinases. The most …

Primary liver cancer is one of the commonest causes of death. Hepatocellular carcinoma
(HCC) accounts for 90% of primary liver cancers. For patients with unresectable or …

Abstract Background Sorafenib (Sor) is the only approved multikinase inhibitor indicated for
the treatment of HCC. Previous studies have shown that amygdalin (Amy) possesses …

Cancer is the first cause of death in developed countries and the second in developing
countries. Concerning the most frequent worldwide-diagnosed cancer, primary liver cancer …

Hepatocellular carcinoma (HCC) is a highly complex cancer, resistant to commonly used
treatments and new therapeutic agents are urgently needed. A total of thirty-two thieno [3, 2 …

BACKGROUND & AIMS: Sorafenib is the standard of care for the treatment of advanced
hepatocellular carcinoma (HCC). However, primary and acquired resistance is observed in …

Cumulative evidences (s) have established that the constitutive activation of STAT3 plays a
pivotal role in the proliferation, survival, metastasis, and angiogenesis and thus can …

As cellular models for in vitro liver cancer and toxicity studies, HepG2 and Hep3B are the
two most frequently used liver cancer cell lines. Because of their similarities they are often …